Enzyme Levels in Lung and Breast Tumors
Author Information
Author(s): A Marinn, A López de Cerain, E Hamilton, AD Lewis, JM Martinez-Peñuela, MA Idoate, J Bello
Primary Institution: Universidad de Navarra
Hypothesis
The levels of reductase enzymes in tumors can influence the effectiveness of bioreductive drugs.
Conclusion
The study found significant variability in the levels of DT-diaphorase in lung and breast tumors compared to normal tissues, suggesting the need for individualized assessment before therapy.
Supporting Evidence
- In 53% of lung tumor samples, DTD activity was increased compared to normal tissue.
- In 70% of breast tumor samples, DTD activity was over 80 nmol min-1 mg-1.
- The study found significant differences in DTD activity based on tumor grade and stage.
Takeaway
This study looked at how certain enzymes in lung and breast tumors can help or hurt cancer treatments, showing that some tumors have much more of these enzymes than normal tissue.
Methodology
The study measured enzyme levels in paired tumor and normal tissue samples from patients using spectrophotometric assays and Western blot analysis.
Potential Biases
Potential bias due to the selection of patients and the variability in tumor types and treatments.
Limitations
The study had a small sample size and did not account for all potential confounding factors affecting enzyme levels.
Participant Demographics
The mean age of lung tumor patients was 65 years, predominantly smokers or ex-smokers; breast tumor patients were all females with a mean age of 51 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website